In Phase C, individuals will get ABBV-744 and oral navitoclax. In Phase D, contributors will get ABBV-744 and ruxolitinib. Members will get treatment right up until sickness progression or even the participants are unable to tolerate the study drugs. Celastrol was determined as being a Myb inhibitor that suppressed C/EBPβ https://kylerfrsdn.boyblogguide.com/31282189/the-2-minute-rule-for-abbv-744-and-other-brd4-inhibitors-comparison